Everything we've seen

1. ·Sep 14, 3:20 PMstreamnews

   Two Medical Device Dividend Giants, One Better Buy: Medtronic vs. Abbott

   Both Medtronic and Abbott have raised their dividends for nearly half a century, but retirement investors with limited capital can only choose one. The case for each is stronger than most comparisons admit, and the tiebreaker comes down to a single question about your timeline.

2. ?Sep 14, 3:20 PMdecisionconsidered

   Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

   ABT is a fundamentally sound large-cap healthcare company (diversified medtech/diagnostics), and the 10% dip from its 30-day high does not appear driven by a confirmed fundamental impairment — no negative headlines or material SEC disclosures explain the drop. However, confirmation signals are notably absent: the CEO sold ~$46M in shares on August 25 (a large, non-trivial insider sale on the dip), options flow shows elevated put volume (P/C ratio 1.23, put z-score +1.17), and the sector flow proxy is deeply negative (-$11M) today. The prior trade was stopped out at $116.81 just 15 days ago, and the stock has since fallen further to $105.58 — the re-entry case requires more than mean reversion, and grounding evidence for a recovery catalyst is thin.

3. !Sep 14, 3:20 PMsignalseverity 0.12

   Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

   ABT is a fundamentally sound large-cap healthcare company (diversified medtech/diagnostics), and the 10% dip from its 30-day high does not appear driven by a confirmed fundamental impairment — no negative headlines or material SEC disclosures explain the drop. However, confirmation signals are notably absent: the CEO sold ~$46M in shares on August 25 (a large, non-trivial insider sale on the dip), options flow shows elevated put volume (P/C ratio 1.23, put z-score +1.17), and the sector flow proxy is deeply negative (-$11M) today. The prior trade was stopped out at $116.81 just 15 days ago, and the stock has since fallen further to $105.58 — the re-entry case requires more than mean reversion, and grounding evidence for a recovery catalyst is thin.

4. ?Sep 14, 3:20 PMdecisionconsidered

   Agent 5 — Dip Buyer (Evolving) — decide: skip

   ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

5. !Sep 14, 3:20 PMsignalseverity 0.12

   Agent 5 — Dip Buyer (Evolving) — dip_skipped

   ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

6. ·Sep 14, 3:05 PMstreamnews

   Two Medical Device Dividend Giants, One Better Buy: Medtronic vs. Abbott

   Both Medtronic and Abbott have raised their dividends for nearly half a century, but retirement investors with limited capital can only choose one. The case for each is stronger than most comparisons admit, and the tiebreaker comes down to a single question about your timeline.

7. ·Sep 14, 2:50 PMstreamnews

   Two Medical Device Dividend Giants, One Better Buy: Medtronic vs. Abbott

   Both Medtronic and Abbott have raised their dividends for nearly half a century, but retirement investors with limited capital can only choose one. The case for each is stronger than most comparisons admit, and the tiebreaker comes down to a single question about your timeline.

8. ·Sep 14, 2:35 PMstreamnews

   Two Medical Device Dividend Giants, One Better Buy: Medtronic vs. Abbott

   Both Medtronic and Abbott have raised their dividends for nearly half a century, but retirement investors with limited capital can only choose one. The case for each is stronger than most comparisons admit, and the tiebreaker comes down to a single question about your timeline.

9. ?Sep 14, 2:20 PMdecisionconsidered

   Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

   ABT is a fundamentally sound large-cap healthcare company (diversified medtech/diagnostics), and the 10% dip from its 30-day high does not appear driven by a confirmed fundamental impairment — no negative headlines or material SEC disclosures explain the drop. However, confirmation signals are notably absent: the CEO sold ~$46M in shares on August 25 (a large, non-trivial insider sale on the dip), options flow shows elevated put volume (P/C ratio 1.23, put z-score +1.17), and the sector flow proxy is deeply negative (-$11M) today. The prior trade was stopped out at $116.81 just 15 days ago, and the stock has since fallen further to $105.58 — the re-entry case requires more than mean reversion, and grounding evidence for a recovery catalyst is thin.

10. !Sep 14, 2:20 PMsignalseverity 0.12

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    ABT is a fundamentally sound large-cap healthcare company (diversified medtech/diagnostics), and the 10% dip from its 30-day high does not appear driven by a confirmed fundamental impairment — no negative headlines or material SEC disclosures explain the drop. However, confirmation signals are notably absent: the CEO sold ~$46M in shares on August 25 (a large, non-trivial insider sale on the dip), options flow shows elevated put volume (P/C ratio 1.23, put z-score +1.17), and the sector flow proxy is deeply negative (-$11M) today. The prior trade was stopped out at $116.81 just 15 days ago, and the stock has since fallen further to $105.58 — the re-entry case requires more than mean reversion, and grounding evidence for a recovery catalyst is thin.

11. ?Sep 14, 2:20 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

12. !Sep 14, 2:20 PMsignalseverity 0.12

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

13. ·Sep 14, 2:20 PMstreamnews

    Abbott reaches agreement with Department of Justice to resolve claims relating to 2022 infant formula recall

    Abbott (NYSE: ABT) has reached an agreement to resolve the previously disclosed investigation and lawsuit brought by the United States Department of Justice, as well as lawsuits filed by certain relators and the Attorneys General of several states, relating to Abbott's manufacturing and 2022 recall of powdered infant formula at its facility in Sturgis, Mich.

14. ·Sep 14, 2:20 PMstreamnews

    Sector Update: Healthcare Stocks Rise in Afternoon Trading

    Healthcare stocks advanced Monday afternoon, with the NYSE Healthcare Index up 1.6% and the State St

15. ❖Sep 14, 1:49 PMnewsvia finnhub

    Sector Update: Healthcare Stocks Rise in Afternoon Trading

    Healthcare stocks advanced Monday afternoon, with the NYSE Healthcare Index up 1.6% and the State St

16. ?Sep 14, 1:20 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

17. !Sep 14, 1:20 PMsignalseverity 0.13

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

18. ?Sep 14, 1:20 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    ABT is a fundamentally sound large-cap healthcare company (diversified medtech/diagnostics), and the 10% dip from its 30-day high does not appear driven by a confirmed fundamental impairment — no negative headlines or material SEC disclosures explain the drop. However, confirmation signals are notably absent: the CEO sold ~$46M in shares on August 25 (a large, non-trivial insider sale on the dip), options flow shows elevated put volume (P/C ratio 1.23, put z-score +1.17), and the sector flow proxy is deeply negative (-$11M) today. The prior trade was stopped out at $116.81 just 15 days ago, and the stock has since fallen further to $105.58 — the re-entry case requires more than mean reversion, and grounding evidence for a recovery catalyst is thin.

19. !Sep 14, 1:20 PMsignalseverity 0.13

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    ABT is a fundamentally sound large-cap healthcare company (diversified medtech/diagnostics), and the 10% dip from its 30-day high does not appear driven by a confirmed fundamental impairment — no negative headlines or material SEC disclosures explain the drop. However, confirmation signals are notably absent: the CEO sold ~$46M in shares on August 25 (a large, non-trivial insider sale on the dip), options flow shows elevated put volume (P/C ratio 1.23, put z-score +1.17), and the sector flow proxy is deeply negative (-$11M) today. The prior trade was stopped out at $116.81 just 15 days ago, and the stock has since fallen further to $105.58 — the re-entry case requires more than mean reversion, and grounding evidence for a recovery catalyst is thin.

20. ?Sep 14, 12:20 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    ABT is a fundamentally sound large-cap healthcare company (diversified medtech/diagnostics), and the 10% dip from its 30-day high does not appear driven by a confirmed fundamental impairment — no negative headlines or material SEC disclosures explain the drop. However, confirmation signals are notably absent: the CEO sold ~$46M in shares on August 25 (a large, non-trivial insider sale on the dip), options flow shows elevated put volume (P/C ratio 1.23, put z-score +1.17), and the sector flow proxy is deeply negative (-$11M) today. The prior trade was stopped out at $116.81 just 15 days ago, and the stock has since fallen further to $105.58 — the re-entry case requires more than mean reversion, and grounding evidence for a recovery catalyst is thin.

21. !Sep 14, 12:20 PMsignalseverity 0.12

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    ABT is a fundamentally sound large-cap healthcare company (diversified medtech/diagnostics), and the 10% dip from its 30-day high does not appear driven by a confirmed fundamental impairment — no negative headlines or material SEC disclosures explain the drop. However, confirmation signals are notably absent: the CEO sold ~$46M in shares on August 25 (a large, non-trivial insider sale on the dip), options flow shows elevated put volume (P/C ratio 1.23, put z-score +1.17), and the sector flow proxy is deeply negative (-$11M) today. The prior trade was stopped out at $116.81 just 15 days ago, and the stock has since fallen further to $105.58 — the re-entry case requires more than mean reversion, and grounding evidence for a recovery catalyst is thin.

22. ?Sep 14, 12:20 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

23. !Sep 14, 12:20 PMsignalseverity 0.12

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

24. ❖Sep 14, 11:52 AMnewsvia finnhub

    Abbott reaches agreement with Department of Justice to resolve claims relating to 2022 infant formula recall

    Abbott (NYSE: ABT) has reached an agreement to resolve the previously disclosed investigation and lawsuit brought by the United States Department of Justice, as well as lawsuits filed by certain relators and the Attorneys General of several states, relating to Abbott's manufacturing and 2022 recall of powdered infant formula at its facility in Sturgis, Mich.

25. ?Sep 14, 11:21 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

26. !Sep 14, 11:21 AMsignalseverity 0.12

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

27. ?Sep 14, 11:21 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    ABT is a fundamentally sound large-cap healthcare company (diversified medtech/diagnostics), and the 10% dip from its 30-day high does not appear driven by a confirmed fundamental impairment — no negative headlines or material SEC disclosures explain the drop. However, confirmation signals are notably absent: the CEO sold ~$46M in shares on August 25 (a large, non-trivial insider sale on the dip), options flow shows elevated put volume (P/C ratio 1.23, put z-score +1.17), and the sector flow proxy is deeply negative (-$11M) today. The prior trade was stopped out at $116.81 just 15 days ago, and the stock has since fallen further to $105.58 — the re-entry case requires more than mean reversion, and grounding evidence for a recovery catalyst is thin.

28. !Sep 14, 11:21 AMsignalseverity 0.12

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    ABT is a fundamentally sound large-cap healthcare company (diversified medtech/diagnostics), and the 10% dip from its 30-day high does not appear driven by a confirmed fundamental impairment — no negative headlines or material SEC disclosures explain the drop. However, confirmation signals are notably absent: the CEO sold ~$46M in shares on August 25 (a large, non-trivial insider sale on the dip), options flow shows elevated put volume (P/C ratio 1.23, put z-score +1.17), and the sector flow proxy is deeply negative (-$11M) today. The prior trade was stopped out at $116.81 just 15 days ago, and the stock has since fallen further to $105.58 — the re-entry case requires more than mean reversion, and grounding evidence for a recovery catalyst is thin.

29. ?Sep 14, 10:21 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    ABT is a fundamentally sound large-cap healthcare company (diversified medtech/diagnostics), and the 10% dip from its 30-day high does not appear driven by a confirmed fundamental impairment — no negative headlines or material SEC disclosures explain the drop. However, confirmation signals are notably absent: the CEO sold ~$46M in shares on August 25 (a large, non-trivial insider sale on the dip), options flow shows elevated put volume (P/C ratio 1.23, put z-score +1.17), and the sector flow proxy is deeply negative (-$11M) today. The prior trade was stopped out at $116.81 just 15 days ago, and the stock has since fallen further to $105.58 — the re-entry case requires more than mean reversion, and grounding evidence for a recovery catalyst is thin.

30. !Sep 14, 10:21 AMsignalseverity 0.12

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    ABT is a fundamentally sound large-cap healthcare company (diversified medtech/diagnostics), and the 10% dip from its 30-day high does not appear driven by a confirmed fundamental impairment — no negative headlines or material SEC disclosures explain the drop. However, confirmation signals are notably absent: the CEO sold ~$46M in shares on August 25 (a large, non-trivial insider sale on the dip), options flow shows elevated put volume (P/C ratio 1.23, put z-score +1.17), and the sector flow proxy is deeply negative (-$11M) today. The prior trade was stopped out at $116.81 just 15 days ago, and the stock has since fallen further to $105.58 — the re-entry case requires more than mean reversion, and grounding evidence for a recovery catalyst is thin.

31. ?Sep 14, 10:21 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

32. !Sep 14, 10:21 AMsignalseverity 0.12

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

33. ?Sep 14, 9:36 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    ABT is up ~2% today with no clear catalytic headline driving the move — the only recent news is a comparative piece with Medtronic, which is neutral to mildly positive for ABT's profile. The absence of a specific negative catalyst means the move is likely organic flow or positioning rather than a news-driven fade setup. The macro context (T10Y2Y at 0.33, slightly below trend) is modestly supportive of defensive/healthcare names like ABT, which tend to hold or benefit in a mild bear-flattening environment. Time remaining is substantial (~370 minutes, roughly full session remaining), giving the move room to extend if institutional buying continues. However, a 2% intraday move in a large-cap defensive like ABT is already meaningful and runs the risk of fading into the close as profit-takers emerge — ABT is not a high-beta name where momentum typically accelerates. No clear reversal pattern is indicated, and volume context is unknown, limiting conviction. Overall, slight lean toward continuation given supportive macro sector backdrop, ample time, and no reversal signal, but not a high-conviction setup.

34. !Sep 14, 9:36 AMsignalseverity 0.02

    Agent 7 — Day Trader — day_trade_skipped

    ABT is up ~2% today with no clear catalytic headline driving the move — the only recent news is a comparative piece with Medtronic, which is neutral to mildly positive for ABT's profile. The absence of a specific negative catalyst means the move is likely organic flow or positioning rather than a news-driven fade setup. The macro context (T10Y2Y at 0.33, slightly below trend) is modestly supportive of defensive/healthcare names like ABT, which tend to hold or benefit in a mild bear-flattening environment. Time remaining is substantial (~370 minutes, roughly full session remaining), giving the move room to extend if institutional buying continues. However, a 2% intraday move in a large-cap defensive like ABT is already meaningful and runs the risk of fading into the close as profit-takers emerge — ABT is not a high-beta name where momentum typically accelerates. No clear reversal pattern is indicated, and volume context is unknown, limiting conviction. Overall, slight lean toward continuation given supportive macro sector backdrop, ample time, and no reversal signal, but not a high-conviction setup.

35. ?Sep 14, 7:01 AMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

36. !Sep 14, 7:01 AMsignalseverity 0.13

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

37. ?Sep 14, 7:00 AMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    ABT is a fundamentally sound large-cap healthcare company (diversified medtech/diagnostics), and the 10% dip from its 30-day high does not appear driven by a confirmed fundamental impairment — no negative headlines or material SEC disclosures explain the drop. However, confirmation signals are notably absent: the CEO sold ~$46M in shares on August 25 (a large, non-trivial insider sale on the dip), options flow shows elevated put volume (P/C ratio 1.23, put z-score +1.17), and the sector flow proxy is deeply negative (-$11M) today. The prior trade was stopped out at $116.81 just 15 days ago, and the stock has since fallen further to $105.58 — the re-entry case requires more than mean reversion, and grounding evidence for a recovery catalyst is thin.

38. !Sep 14, 7:00 AMsignalseverity 0.13

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    ABT is a fundamentally sound large-cap healthcare company (diversified medtech/diagnostics), and the 10% dip from its 30-day high does not appear driven by a confirmed fundamental impairment — no negative headlines or material SEC disclosures explain the drop. However, confirmation signals are notably absent: the CEO sold ~$46M in shares on August 25 (a large, non-trivial insider sale on the dip), options flow shows elevated put volume (P/C ratio 1.23, put z-score +1.17), and the sector flow proxy is deeply negative (-$11M) today. The prior trade was stopped out at $116.81 just 15 days ago, and the stock has since fallen further to $105.58 — the re-entry case requires more than mean reversion, and grounding evidence for a recovery catalyst is thin.

39. ❖Sep 13, 10:36 AMnewsvia finnhub

    Two Medical Device Dividend Giants, One Better Buy: Medtronic vs. Abbott

    Both Medtronic and Abbott have raised their dividends for nearly half a century, but retirement investors with limited capital can only choose one. The case for each is stronger than most comparisons admit, and the tiebreaker comes down to a single question about your timeline.

40. ✓Sep 11, 6:04 PMdecisionacted

    Agent 4 — Dip Buyer (Frozen) — decide: buy

    Abbott Laboratories (ABT) is a diversified, investment-grade medical device and diagnostics company with a long track record of stable earnings and dividend growth, making it fundamentally sound in the absence of any negative company-specific news. The 13.1% drawdown from the 30-day high appears to be macro-driven rather than fundamental deterioration — no earnings warnings, guidance cuts, or accounting issues appear in the available evidence. The primary headwind is the elevated 5-year forward inflation rate (T5YIFR at 1.8σ above trend), which pressures rate-sensitive and high-multiple healthcare names, but ABT's defensive characteristics and diversified revenue base provide resilience.

41. ?Sep 11, 4:20 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

42. !Sep 11, 4:20 PMsignalseverity 0.13

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

43. ?Sep 11, 4:20 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    ABT is a fundamentally sound large-cap healthcare company (diversified medtech/diagnostics), and the 10% dip from its 30-day high does not appear driven by a confirmed fundamental impairment — no negative headlines or material SEC disclosures explain the drop. However, confirmation signals are notably absent: the CEO sold ~$46M in shares on August 25 (a large, non-trivial insider sale on the dip), options flow shows elevated put volume (P/C ratio 1.23, put z-score +1.17), and the sector flow proxy is deeply negative (-$11M) today. The prior trade was stopped out at $116.81 just 15 days ago, and the stock has since fallen further to $105.58 — the re-entry case requires more than mean reversion, and grounding evidence for a recovery catalyst is thin.

44. !Sep 11, 4:20 PMsignalseverity 0.13

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    ABT is a fundamentally sound large-cap healthcare company (diversified medtech/diagnostics), and the 10% dip from its 30-day high does not appear driven by a confirmed fundamental impairment — no negative headlines or material SEC disclosures explain the drop. However, confirmation signals are notably absent: the CEO sold ~$46M in shares on August 25 (a large, non-trivial insider sale on the dip), options flow shows elevated put volume (P/C ratio 1.23, put z-score +1.17), and the sector flow proxy is deeply negative (-$11M) today. The prior trade was stopped out at $116.81 just 15 days ago, and the stock has since fallen further to $105.58 — the re-entry case requires more than mean reversion, and grounding evidence for a recovery catalyst is thin.

45. ?Sep 11, 3:20 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    ABT is a fundamentally sound large-cap healthcare company (diversified medtech/diagnostics), and the 10% dip from its 30-day high does not appear driven by a confirmed fundamental impairment — no negative headlines or material SEC disclosures explain the drop. However, confirmation signals are notably absent: the CEO sold ~$46M in shares on August 25 (a large, non-trivial insider sale on the dip), options flow shows elevated put volume (P/C ratio 1.23, put z-score +1.17), and the sector flow proxy is deeply negative (-$11M) today. The prior trade was stopped out at $116.81 just 15 days ago, and the stock has since fallen further to $105.58 — the re-entry case requires more than mean reversion, and grounding evidence for a recovery catalyst is thin.

46. !Sep 11, 3:20 PMsignalseverity 0.13

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    ABT is a fundamentally sound large-cap healthcare company (diversified medtech/diagnostics), and the 10% dip from its 30-day high does not appear driven by a confirmed fundamental impairment — no negative headlines or material SEC disclosures explain the drop. However, confirmation signals are notably absent: the CEO sold ~$46M in shares on August 25 (a large, non-trivial insider sale on the dip), options flow shows elevated put volume (P/C ratio 1.23, put z-score +1.17), and the sector flow proxy is deeply negative (-$11M) today. The prior trade was stopped out at $116.81 just 15 days ago, and the stock has since fallen further to $105.58 — the re-entry case requires more than mean reversion, and grounding evidence for a recovery catalyst is thin.

47. ?Sep 11, 3:20 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

48. !Sep 11, 3:20 PMsignalseverity 0.13

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

49. ?Sep 11, 2:21 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    ABT is a fundamentally sound large-cap healthcare company (diversified medtech/diagnostics), and the 10% dip from its 30-day high does not appear driven by a confirmed fundamental impairment — no negative headlines or material SEC disclosures explain the drop. However, confirmation signals are notably absent: the CEO sold ~$46M in shares on August 25 (a large, non-trivial insider sale on the dip), options flow shows elevated put volume (P/C ratio 1.23, put z-score +1.17), and the sector flow proxy is deeply negative (-$11M) today. The prior trade was stopped out at $116.81 just 15 days ago, and the stock has since fallen further to $105.58 — the re-entry case requires more than mean reversion, and grounding evidence for a recovery catalyst is thin.

50. !Sep 11, 2:21 PMsignalseverity 0.13

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    ABT is a fundamentally sound large-cap healthcare company (diversified medtech/diagnostics), and the 10% dip from its 30-day high does not appear driven by a confirmed fundamental impairment — no negative headlines or material SEC disclosures explain the drop. However, confirmation signals are notably absent: the CEO sold ~$46M in shares on August 25 (a large, non-trivial insider sale on the dip), options flow shows elevated put volume (P/C ratio 1.23, put z-score +1.17), and the sector flow proxy is deeply negative (-$11M) today. The prior trade was stopped out at $116.81 just 15 days ago, and the stock has since fallen further to $105.58 — the re-entry case requires more than mean reversion, and grounding evidence for a recovery catalyst is thin.

51. ?Sep 11, 2:21 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

52. !Sep 11, 2:21 PMsignalseverity 0.13

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

53. ?Sep 11, 1:20 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    ABT is a fundamentally sound large-cap healthcare company (diversified medtech/diagnostics), and the 10% dip from its 30-day high does not appear driven by a confirmed fundamental impairment — no negative headlines or material SEC disclosures explain the drop. However, confirmation signals are notably absent: the CEO sold ~$46M in shares on August 25 (a large, non-trivial insider sale on the dip), options flow shows elevated put volume (P/C ratio 1.23, put z-score +1.17), and the sector flow proxy is deeply negative (-$11M) today. The prior trade was stopped out at $116.81 just 15 days ago, and the stock has since fallen further to $105.58 — the re-entry case requires more than mean reversion, and grounding evidence for a recovery catalyst is thin.

54. !Sep 11, 1:20 PMsignalseverity 0.13

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    ABT is a fundamentally sound large-cap healthcare company (diversified medtech/diagnostics), and the 10% dip from its 30-day high does not appear driven by a confirmed fundamental impairment — no negative headlines or material SEC disclosures explain the drop. However, confirmation signals are notably absent: the CEO sold ~$46M in shares on August 25 (a large, non-trivial insider sale on the dip), options flow shows elevated put volume (P/C ratio 1.23, put z-score +1.17), and the sector flow proxy is deeply negative (-$11M) today. The prior trade was stopped out at $116.81 just 15 days ago, and the stock has since fallen further to $105.58 — the re-entry case requires more than mean reversion, and grounding evidence for a recovery catalyst is thin.

55. ?Sep 11, 1:20 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

56. !Sep 11, 1:20 PMsignalseverity 0.13

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

57. ?Sep 11, 12:21 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    ABT is a fundamentally sound large-cap healthcare company (diversified medtech/diagnostics), and the 10% dip from its 30-day high does not appear driven by a confirmed fundamental impairment — no negative headlines or material SEC disclosures explain the drop. However, confirmation signals are notably absent: the CEO sold ~$46M in shares on August 25 (a large, non-trivial insider sale on the dip), options flow shows elevated put volume (P/C ratio 1.23, put z-score +1.17), and the sector flow proxy is deeply negative (-$11M) today. The prior trade was stopped out at $116.81 just 15 days ago, and the stock has since fallen further to $105.58 — the re-entry case requires more than mean reversion, and grounding evidence for a recovery catalyst is thin.

58. !Sep 11, 12:21 PMsignalseverity 0.13

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    ABT is a fundamentally sound large-cap healthcare company (diversified medtech/diagnostics), and the 10% dip from its 30-day high does not appear driven by a confirmed fundamental impairment — no negative headlines or material SEC disclosures explain the drop. However, confirmation signals are notably absent: the CEO sold ~$46M in shares on August 25 (a large, non-trivial insider sale on the dip), options flow shows elevated put volume (P/C ratio 1.23, put z-score +1.17), and the sector flow proxy is deeply negative (-$11M) today. The prior trade was stopped out at $116.81 just 15 days ago, and the stock has since fallen further to $105.58 — the re-entry case requires more than mean reversion, and grounding evidence for a recovery catalyst is thin.

59. ?Sep 11, 12:20 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

60. !Sep 11, 12:20 PMsignalseverity 0.13

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

61. ❖Sep 11, 9:00 AMnewsvia finnhub

    Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know

    Abbott (ABT) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

62. ❖Sep 11, 5:20 AMnewsvia finnhub

    The Zacks Analyst Blog Highlights Goldman Sachs, RTX, Abbott, NLI and Precipio

    Goldman Sachs, RTX and Abbott lead Zacks' latest research, with growth drivers balanced by costs, supply-chain and market risks.

63. ?Sep 10, 4:26 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

64. !Sep 10, 4:26 PMsignalseverity 0.12

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

65. ?Sep 10, 4:26 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    ABT is a fundamentally sound large-cap healthcare company (diversified medtech/diagnostics), and the 10% dip from its 30-day high does not appear driven by a confirmed fundamental impairment — no negative headlines or material SEC disclosures explain the drop. However, confirmation signals are notably absent: the CEO sold ~$46M in shares on August 25 (a large, non-trivial insider sale on the dip), options flow shows elevated put volume (P/C ratio 1.23, put z-score +1.17), and the sector flow proxy is deeply negative (-$11M) today. The prior trade was stopped out at $116.81 just 15 days ago, and the stock has since fallen further to $105.58 — the re-entry case requires more than mean reversion, and grounding evidence for a recovery catalyst is thin.

66. !Sep 10, 4:26 PMsignalseverity 0.12

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    ABT is a fundamentally sound large-cap healthcare company (diversified medtech/diagnostics), and the 10% dip from its 30-day high does not appear driven by a confirmed fundamental impairment — no negative headlines or material SEC disclosures explain the drop. However, confirmation signals are notably absent: the CEO sold ~$46M in shares on August 25 (a large, non-trivial insider sale on the dip), options flow shows elevated put volume (P/C ratio 1.23, put z-score +1.17), and the sector flow proxy is deeply negative (-$11M) today. The prior trade was stopped out at $116.81 just 15 days ago, and the stock has since fallen further to $105.58 — the re-entry case requires more than mean reversion, and grounding evidence for a recovery catalyst is thin.

67. ❖Sep 10, 4:12 PMnewsvia finnhub

    Top Research Reports for Goldman Sachs, RTX & Abbott

    Goldman Sachs, RTX and Abbott headline today's research, with growth drivers, risks and strategic moves shaping their outlooks.

68. ?Sep 10, 3:25 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    ABT is down 1.68% with only 20 minutes remaining until the forced close. The move is meaningful but not outsized (under 2%), and critically, the time constraint is severe — 20 minutes leaves very little runway for continuation to reach the +3% profit target, while the -1.5% stop is also compressed. No catalyzing headlines are present to sustain directional flow. The macro context shows elevated 5-year forward inflation expectations (2.33, ~1.6σ above trend), which is modestly negative for rate-sensitive sectors, but ABT as a medical device/healthcare name is only indirectly rate-sensitive and this macro factor is not a strong near-term driver. With this little time remaining, the dominant dynamic into the close is likely positioning squaring and mean reversion rather than continuation. The risk/reward of chasing a sub-2% move with 20 minutes left does not meet the threshold — fading or flat is the higher-probability outcome.

69. !Sep 10, 3:25 PMsignalseverity -0.02

    Agent 7 — Day Trader — day_trade_skipped

    ABT is down 1.68% with only 20 minutes remaining until the forced close. The move is meaningful but not outsized (under 2%), and critically, the time constraint is severe — 20 minutes leaves very little runway for continuation to reach the +3% profit target, while the -1.5% stop is also compressed. No catalyzing headlines are present to sustain directional flow. The macro context shows elevated 5-year forward inflation expectations (2.33, ~1.6σ above trend), which is modestly negative for rate-sensitive sectors, but ABT as a medical device/healthcare name is only indirectly rate-sensitive and this macro factor is not a strong near-term driver. With this little time remaining, the dominant dynamic into the close is likely positioning squaring and mean reversion rather than continuation. The risk/reward of chasing a sub-2% move with 20 minutes left does not meet the threshold — fading or flat is the higher-probability outcome.

70. ?Sep 9, 4:25 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    ABT is a fundamentally sound large-cap healthcare company (diversified medtech/diagnostics), and the 10% dip from its 30-day high does not appear driven by a confirmed fundamental impairment — no negative headlines or material SEC disclosures explain the drop. However, confirmation signals are notably absent: the CEO sold ~$46M in shares on August 25 (a large, non-trivial insider sale on the dip), options flow shows elevated put volume (P/C ratio 1.23, put z-score +1.17), and the sector flow proxy is deeply negative (-$11M) today. The prior trade was stopped out at $116.81 just 15 days ago, and the stock has since fallen further to $105.58 — the re-entry case requires more than mean reversion, and grounding evidence for a recovery catalyst is thin.

71. !Sep 9, 4:25 PMsignalseverity 0.10

    Agent 8 — Dip Buyer (Peer-Aware) — dip_skipped

    ABT is a fundamentally sound large-cap healthcare company (diversified medtech/diagnostics), and the 10% dip from its 30-day high does not appear driven by a confirmed fundamental impairment — no negative headlines or material SEC disclosures explain the drop. However, confirmation signals are notably absent: the CEO sold ~$46M in shares on August 25 (a large, non-trivial insider sale on the dip), options flow shows elevated put volume (P/C ratio 1.23, put z-score +1.17), and the sector flow proxy is deeply negative (-$11M) today. The prior trade was stopped out at $116.81 just 15 days ago, and the stock has since fallen further to $105.58 — the re-entry case requires more than mean reversion, and grounding evidence for a recovery catalyst is thin.

72. ?Sep 9, 4:25 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

73. !Sep 9, 4:25 PMsignalseverity 0.10

    Agent 5 — Dip Buyer (Evolving) — dip_skipped

    ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

74. ❖Sep 9, 2:06 PMnewsvia finnhub

    BSX Stock: Is It Time To Buy Or Sell Puts?

    Trading near $45 a share, Boston Scientific (BSX) sits roughly 58% below its 52-week peak. Instead of buying the dip outright, selling cash-secured put options allows investors to generate immediate income while locking in an even deeper entry point. Sell a put option on BSX expiring 9/17/2027, with a strike price of $30.

75. ❖Sep 9, 11:40 AMnewsvia finnhub

    NVST or ABT: Which Is the Better Value Stock Right Now?

    NVST vs. ABT: Which Stock Is the Better Value Option?

76. ❖Sep 9, 10:30 AMnewsvia finnhub

    Abbott Receives FDA Nod for TactiFlex Duo: Stock to Gain?

    FDA approval for TactiFlex Duo expands ABT's AFib ablation portfolio with dual PFA and RF energy options, supporting broader U.S. adoption.

77. ❖Sep 9, 9:12 AMnewsvia finnhub

    Medtronic Raises 2027 Outlook as Broad-Based Growth Gains Momentum

    MDT lifts its 2027 outlook as broad-based growth accelerates, but margin pressure and competition could test momentum.

78. ❖Sep 9, 6:56 AMnewsvia finnhub

    Abbott’s dual ablation catheter lands FDA approval

    FDA clearance for Abbott’s TactiFlex Duo follows the dual ablation catheter’s receipt of a European CE mark in January 2026.

79. ❖Sep 9, 4:00 AMnewsvia finnhub

    Giovanni Caforio Appointed Operating Advisor to CD&R Funds

    CD&R (or the "Firm") today announced the appointment of Giovanni Caforio as an Operating Advisor to CD&R funds. The Firm believes his 35-year career in the international biopharmaceutical industry will be invaluable as he supports CD&R funds in identifying and evaluating new investment opportunities within healthcare, as well as working with its portfolio companies globally.

80. ?Sep 8, 4:22 PMdecisionconsidered

    Agent 5 — Dip Buyer (Evolving) — decide: skip

    ABT is a fundamentally sound large-cap healthcare company, and no 10-Q/8-K metrics indicate deterioration, guidance cuts, or going-concern issues. However, the signal stack is net negative: earnings are 35 days away (a meaningful headwind, -1), the CEO made two large clustered sales totaling ~$46M on 8/25 (-1), options flow skews bearish with a P/C ratio of 1.23 and elevated put z-score (+1.17 vs call z=-0.63, -1), and the 10Y yield at 4.77% is above the 4.5% threshold (-1). On the positive side, ABT's sector (Healthcare) is outperforming SPY over 30 days, which actually works against this as a positive signal—the drop appears more idiosyncratic. The drop is only 10%, below the 15% mean-reversion threshold, and macro is not in acute crisis (VIX at 12th percentile). Net signal score is approximately -3 to -2, keeping rebound probability below the 0.50 buy threshold despite the base rate anchor.

81. ?Sep 8, 4:22 PMdecisionconsidered

    Agent 8 — Dip Buyer (Peer-Aware) — decide: skip

    ABT is a fundamentally sound large-cap healthcare company (diversified medtech/diagnostics), and the 10% dip from its 30-day high does not appear driven by a confirmed fundamental impairment — no negative headlines or material SEC disclosures explain the drop. However, confirmation signals are notably absent: the CEO sold ~$46M in shares on August 25 (a large, non-trivial insider sale on the dip), options flow shows elevated put volume (P/C ratio 1.23, put z-score +1.17), and the sector flow proxy is deeply negative (-$11M) today. The prior trade was stopped out at $116.81 just 15 days ago, and the stock has since fallen further to $105.58 — the re-entry case requires more than mean reversion, and grounding evidence for a recovery catalyst is thin.

82. ?Sep 8, 10:25 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    ABT is down 2.04% with no identifiable news catalyst, suggesting this is likely institutional flow or sector rotation pressure. With 320 minutes remaining (essentially a full afternoon session), there is ample time for continuation. The macro context shows the 5-year forward inflation rate running 1.7σ above trend, which creates a headwind for rate-sensitive sectors — ABT as a large-cap healthcare/medtech name with predictable cash flows can be pressured in elevated-rate-expectation environments. No reversal signals are evident from the data provided, and no headlines suggest a headline-driven pop is imminent. The move is at the lower boundary of the 'meaningful conviction' range (2-5%), so while real selling is occurring, it lacks the full conviction signature of a 3%+ move. Without volume data to confirm or deny thinness, and with no news to reverse the narrative, the base case is modest continuation into the close. Probability stays at the lower end of the continuation range given the absence of corroborating volume/sector data.

83. ?Sep 2, 3:40 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    Only 5 minutes remain until the forced 3:45 PM ET close, which severely limits any meaningful continuation. The 1.66% move is modest and below the threshold where momentum alone would be compelling. No catalytic headlines are present, and the macro context (elevated 5Y5Y inflation forward at 1.7σ above trend) is mildly unfavorable for rate-sensitive names like ABT, which trades at a premium multiple and is sensitive to discount rate assumptions. With virtually no time left in the session, even a constructive setup cannot generate meaningful additional upside before forced flatten. The risk/reward of entering here with only 5 minutes to run is poor — the +3% target is unreachable and the -1.5% stop remains live. Declining to take the position.

84. ?Sep 2, 11:35 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    ABT is up 2.83% today with no attributable headline, suggesting this is flow/positioning-driven rather than news-driven. The move is meaningful in size and represents real conviction from institutional participants. With 250 minutes remaining (over 4 hours), there is ample time for continuation into the close. The macro context shows 5-year forward inflation expectations elevated at 1.7σ above trend, which creates a mildly headwind for rate-sensitive sectors broadly — ABT as a large-cap healthcare/medtech name has some rate sensitivity but is not a pure rate play. No reversal signals are evident from the data provided. In the absence of a fade pattern or clear macro headwind specific to this name, the default lean is mild continuation. However, without volume confirmation data or a clear catalyst, conviction stays in the moderate range rather than high. Taking the position with standard momentum bias.

85. ?Sep 1, 9:37 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    ABT is up 2.08% today with no attributable headline, suggesting institutional flow driving the move. The magnitude is meaningful but not extreme — consistent with a conviction bid rather than a news spike that might reverse. Time remaining is substantial (369 minutes, essentially the full afternoon session), giving the move ample runway to continue into the close. The macro context (2Y yields elevated at ~4.34%, 2σ above trend) is a mild headwind for growth-sensitive names, but ABT is a defensive healthcare/medtech name with limited direct sensitivity to short-duration rate pressure — this macro factor is largely neutral here. No reversal signals are evident from the data provided. The absence of news is not a disqualifier; large-cap medtech names frequently see accumulation flows mid-session without a specific catalyst. With no strong fade signals, ample time, and meaningful upside momentum already established, the default lean is continuation, though the lack of confirming news or sector tailwind keeps conviction modest.

86. ?Aug 31, 12:10 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    ABT is down 2.25% with 215 minutes remaining — a meaningful move with ample time to continue. No headline is attributable, suggesting this may be institutional flow or sector rotation rather than a news-driven spike prone to quick reversal. The macro context (elevated mortgage rates at 1.8σ above trend) is not directly relevant to ABT as a medical device/healthcare company, offering neither tailwind nor headwind to reverse the move. With no counter-catalyst visible, the default lean is mild continuation. However, the absence of any identifiable catalyst and the fact that 2.25% is near the lower bound of the 2-5% 'high conviction' threshold tempers confidence. No reversal pattern is evident from the data provided. Overall: modest continuation probability, enough to favor a short-side position given the bounded risk structure.

87. ?Aug 31, 10:31 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    ABT is down 1.54% with 315 minutes remaining — a meaningful move but not yet in the 2-5% range that would signal heavy conviction flow. There are no headlines to anchor the thesis in either direction. The macro context (elevated mortgage rates) is not directly relevant to ABT, a diversified healthcare/medtech name, so no sector tailwind or headwind applies here. With over 5 hours of session remaining, there is ample time for continuation, but also ample time for a mean-reversion fade, especially absent a catalytic driver. The move size sits in the moderate range where momentum alone is borderline. No reversal pattern is evident from the data provided, and no thin-volume warning is flagged. Given the system's bounded risk profile and the instruction to lean toward continuation on borderline reads, I assign a continuation probability at the floor threshold — the evidence does not argue strongly for fade, but neither does it provide clear conviction for further downside.

88. ?Aug 28, 9:51 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    ABT is down 2.20% intraday with no attributable headline, suggesting this is flow-driven selling rather than a news catalyst. The move is meaningful in magnitude — representing real conviction from someone with size. However, several factors temper enthusiasm for continuation: (1) The macro context (elevated mortgage rates at 1.8σ above trend) is not directly sector-relevant for ABT, a medical devices/healthcare conglomerate, offering no tailwind to the selling thesis. (2) With 355 minutes remaining (nearly a full trading day's worth of time relative to a 6.5-hour session, suggesting we are very early in the session), there is ample time for either continuation or mean reversion — this cuts both ways. (3) Absence of a news catalyst means the move could be driven by a single large seller who may exhaust their order, leading to stabilization or reversal. (4) ABT has no clear sector linkage to the elevated mortgage rate environment that dominates today's macro narrative. On balance, the magnitude of the move and the principle that real flow tends to persist slightly longer than intuition suggests push the probability just above 0.5, but this is a borderline read with modest conviction. The tight stop structure makes it worth engaging, but this is not a high-conviction setup.

89. ?Aug 27, 2:05 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    ABT is down 1.79% today, which is a meaningful but not extreme move. No news headlines are available to explain the decline, so this is likely technical or broad market flow. The macro context (elevated mortgage rates at 1.8σ above trend) is most directly relevant to homebuilders, REITs, and banks — ABT as a healthcare/medical devices company has minimal direct sensitivity to mortgage rates, so macro is neither a tailwind nor a headwind for continuation. With 100 minutes remaining there is reasonable time for the move to continue, but without a clear catalyst or sector-level pressure, the setup is borderline. The move is real flow and must be respected, but the absence of any supporting news or sector-specific macro pressure limits conviction. Assigning exactly 0.5 — momentum is the only evidence and it is insufficient to push higher but not enough to fade.

90. ?Aug 27, 11:56 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    ABT is down -1.59% today, a moderate but not dramatic intraday move. There are no news catalysts to explain the drop, which cuts both ways — no clear fundamental driver means the move could be noise or institutional repositioning without a lasting thesis. The macro context shows 5Y5Y inflation forwards elevated at 1.6σ above trend, which is modestly bearish for rate-sensitive sectors and healthcare broadly, providing a mild tailwind for continuation lower. However, with 230 minutes remaining the session is still early-to-mid, so there is ample time for either continuation or reversal. The move is below the 2% threshold where momentum becomes more self-sustaining, and without volume data or a news catalyst, conviction is limited. The absence of a reversal signal and the mildly negative macro backdrop tip this slightly toward continuation, but only marginally — this is a borderline read. Taking the down side at the minimum threshold given the bounded risk profile of the strategy.

91. ?Aug 27, 10:11 AMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    ABT is down 1.54% with 334 minutes remaining — meaningful time for continuation, but the move sits just below the 2% threshold that would signal stronger institutional conviction. No news catalyst is present to explain the move, which cuts both ways: could be quiet distribution or simply sector rotation. The macro backdrop shows the 5-year forward inflation rate (T5YIFR) printing 1.6σ above its 24-month trend, suggesting elevated rate pressure. ABT as a large-cap healthcare/medtech name has some rate sensitivity (discounted cash flows on growth segments, dividend yield compression), which could provide modest headwind supporting the down move. However, ABT is not a pure rate-sensitive play — it has defensive characteristics that tend to attract buying on dips. With no clear catalyst and a relatively modest move, the setup lacks the conviction signal needed to push above 0.5. The absence of news and the defensive nature of the name increase the probability of mean reversion or stabilization into the close rather than continuation. Probability of continuation down is marginally below the trigger threshold.

92. ?Aug 26, 3:35 PMdecisionconsidered

    Agent 7 — Day Trader — decide: skip

    With only 10 minutes remaining until the forced close, there is minimal time for the move to extend meaningfully. ABT is down 1.58%, which is a moderate but not extreme intraday move. The macro context shows elevated 5-year forward inflation expectations (T5YIFR 1.6σ above trend), which is modestly negative for rate-sensitive sectors, but ABT as a large-cap healthcare/medtech name has limited direct sensitivity to this factor. No news headlines are present to explain the move or sustain directional pressure. With the session essentially over, late-day dynamics often involve profit-taking on short positions or covering, which would work against continuation. The extremely short time window is the dominant factor here — even a valid continuation setup has almost no runway left, making the risk/reward of a down continuation trade unfavorable.

93. ❖Aug 24, 12:52 AMnewsvia finnhub

    Best Dividend Kings: August 2026

    Dividend Kings beat the S&P 500 YTD, with 30 topping SPY and 25 looking undervalued with 10%+ return potential.

94. ▣Aug 23, 8:00 PMjournaltime_stop

    Agent 8 — Dip Buyer (Peer-Aware) closed long 13 @ $116.81 (+$378.16)

    Time stop: held 97 ≥ 90 days

95. ❖Aug 10, 6:46 PMnewsvia finnhub

    Abbott vs. Medtronic: Is Consistent Growth Better Than a Turnaround Story?

    Abbott Laboratories (NYSE:ABT) and Medtronic (NYSE:MDT) are both prominent names in the Medtech space. Abbott Laboratories (NYSE:ABT) delivered strong fiscal Q2 2026 results, beating quarterly estimates and raising its annual profit forecast as robust demand for its cancer diagnostics and medical devices businesses helped ease investor concerns surrounding procedure volumes. Medtronic (NYSE:MDT), meanwhile, continued to […]

96. ❖Aug 10, 4:49 PMnewsvia finnhub

    Johnson & Johnson vs Abbott Laboratories: Which Healthcare Giant Offers the More Compelling Growth Story After Earnings?

    Johnson & Johnson (NYSE:JNJ) delivered strong fiscal Q2 2026 results, with sales for the quarter growing nearly 7% to $25.31 ⁠billion, above analysts’ average estimate of about $25.05 billion. Adjusted earnings per share reached $2.90, surpassing the expectation of $2.85. The company also raised its guidance and stated that it is on track to meet […]

97. ❖Aug 10, 2:14 PMnewsvia finnhub

    Boston Scientific Stock Is Priced As If WATCHMAN Were The Whole Company

    Two stalled franchises forced the guidance cut, and they sit outside the three quarters of revenue management still expects to grow at its long-run pace, with the shares now near the bottom of their decade on sales.

98. ❖Aug 10, 10:43 AMnewsvia finnhub

    Should You Buy, Hold or Sell ABT Stock Amid Medical Devices Boom?

    Abbott's Medical Devices growth, EPD momentum and improving Nutrition support its outlook, but China risks, costs and valuation warrant caution.

99. ❖Aug 8, 12:11 PMnewsvia finnhub

    Abbott Laboratories (ABT) Could Be 10% Undervalued On Its $1.35b Buyback Update

    Abbott Laboratories buyback update Abbott Laboratories (ABT) has completed a share repurchase tranche that saw the company buy back 14,015,097 shares for about US$1.35b, including 11,599,094 shares between April and June 2026. See our latest analysis for Abbott Laboratories. Abbott Laboratories shares trade at US$107.81 and have gained 27.86% over the past 90 days, while the year-to-date share price return is down 13.19% and the 1-year total shareholder return is down 17.86%. This points to...

100. ❖Aug 7, 4:44 PMnewsvia finnhub

     AbbVie vs. Abbott Laboratories: Which Healthcare Stock Is a Better Buy in 2026?

     AbbVie generates stronger free cash flow and trades at a lower forward multiple, while Abbott offers diversification and a healthier balance sheet.

101. ❖Aug 7, 1:58 PMnewsvia finnhub

     HQH: After Biotech's Breakout Year, This Healthcare CEF Still Trades Below NAV; Buy

     Abrdn Healthcare Investors biotech CEF: 6.4% NAV discount, 56% NAV gain, 12% gain-funded payout, key risks. Read my analysis here on HQH.

102. ❖Aug 7, 1:54 PMnewsvia finnhub

     Dividend Champion, Contender, And Challenger Highlights: Week Of August 9

     Weekly dividend activity roundup for Dividend Champions, Contenders & Challengers—see dividend changes, upcoming ex-dividend dates and pay dates here.

103. ❖Aug 7, 11:40 AMnewsvia finnhub

     NVST vs. ABT: Which Stock Is the Better Value Option?

     NVST vs. ABT: Which Stock Is the Better Value Option?

104. ❖Aug 7, 10:49 AMnewsvia finnhub

     Here's How ABT Broadens Diagnostics Growth Base With Oncology Expansion

     Abbott broadens Diagnostics growth with Exact Sciences, as Cancer Diagnostics gains and resilient routine testing offset respiratory weakness.

105. ❖Aug 7, 9:00 AMnewsvia finnhub

     Don’t Want to Pay a Lot of Taxes? Move Your Company to This Tiny Mediterranean Archipelago.

     Malta is the smallest country in the EU, but it's become a big tax haven for U.S. companies.

106. ❖Aug 7, 8:37 AMnewsvia finnhub

     What Makes Abbott Laboratories (ABT) a Compelling Investment Opportunity with Reliable Growth

     Matrix Asset Advisors, an asset management company, released its Q2 2026 investor letter. A copy of the letter can be downloaded here. The stock market rebounded strongly in the second quarter, with the S&P 500 gaining 15.2% in the quarter and 10.2% year-to-date. Investors overlooked inflation concerns exceeding 4% and geopolitical tensions, focusing instead on […]

107. ❖Aug 6, 3:30 PMnewsvia finnhub

     [Latest] Global Nutritional Market Size/Share Worth USD 1,819.6 Billion by 2034 at a 10.6% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

     [220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Nutritional Market size & share revenue was valued at approximately USD 660.6 Billion in 2024 and is expected to reach USD 731.9 Billion in 2025 and is expected to reach around USD 1,819.6 Billion by 2034, at a CAGR of 10.6% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Glanbia Plc, Abbott Laboratorie

108. ❖Aug 6, 11:32 AMnewsvia finnhub

     Becton Dickinson Lifts Full-Year Profit Outlook as Third-Quarter Results Top Views

     Becton Dickinson (BDX) raised its full-year earnings guidance as the medical device maker's third-qu

109. ❖Aug 6, 10:38 AMnewsvia finnhub

     Boston Scientific's 2026 Guidance Cut Puts Its Recovery to the Test

     Boston Scientific's 2026 guidance cut tests its recovery as WATCHMAN weakness, EP share losses and delayed margin gains push a broader rebound toward 2028.

110. ❖Aug 6, 9:47 AMnewsvia finnhub

     Abbott Stock: Is Wall Street Bullish or Bearish?

     Abbott has lagged behind the broader market over the past year, yet analysts remain highly bullish about the stock’s prospects.

111. ❖Aug 5, 3:30 PMnewsvia finnhub

     [Latest] Global Deep Eutectic Solvents Market Size/Share Worth USD 735.89 Million by 2034 at a 15.27% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

     [220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Deep Eutectic Solvents Market size & share revenue was valued at approximately USD 177.64 Million in 2024 and is expected to reach USD 204.77 Million in 2025 and is expected to reach around USD 735.89 Million by 2034, at a CAGR of 15.27% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Proionic GmbH, Iol

112. ❖Aug 4, 3:44 PMnewsvia finnhub

     Meet the Columbus Partnership's Roster of 83 Business and Civic Leaders

     The nonprofit civic organization, which includes many of the Columbus region’s top CEOs and institutional leaders, has 83 members as of August 2026.

113. ❖Aug 4, 12:55 PMnewsvia finnhub

     Abbott vs Danaher: Which Healthcare Stock Looks Better Positioned Following Earnings?

     Abbott Laboratories (NYSE:ABT) delivered strong fiscal Q2 2026 results, beating quarterly estimates and raising its annual profit forecast as robust demand for its cancer diagnostics and medical devices businesses helped ease investor concerns surrounding procedure volumes. Sales for the quarter rose 13% on a reported basis and 4.8% on a comparable basis. Danaher Corporation’s (NYSE:DHR) […]

114. ?Aug 4, 9:46 AMdecisionconsidered

     Agent 7 — Day Trader — decide: skip

     ABT is down 1.54% with 360 minutes (6 hours) remaining — effectively a full trading day still ahead, so time is not a constraint on continuation. The move is moderate but not extreme. There is no ABT-specific headline driving the decline, and the macro context (5Y inflation breakevens 1.5σ below trend) is mildly risk-supportive for equities (lower inflation expectations = less Fed tightening pressure), which could act as a mild headwind to further downside rather than a tailwind. The sole headline is entirely unrelated to ABT. With no clear catalyst amplifying the move and a marginally supportive macro backdrop, this is a borderline read. The 1.54% move represents real flow but does not signal the kind of conviction that typically produces sustained intraday trending. Assigning 0.5 — minimum threshold to take the trade given the system's bounded risk structure, but no strong edge identified.

115. ❖Aug 3, 11:45 PMnewsvia finnhub

     SCHD’s 0.06% Fee Hides the Real Cost: How March Reconstitution Triggered $0.8241 Per Share in Surprise Distributions

     SCHD charges just 0.06% per year, but taxable investors who lived through the March reconstitution discovered a second bill arriving in a very different form. Here is what the expense ratio line was never designed to show you.

116. ❖Aug 3, 11:44 AMnewsvia finnhub

     Abbott Laboratories Lost 16% This Year: One Analyst Sees 35% Gains for the Healthcare Giant

     Abbott Laboratories has shed billions in market value this year while the broader market climbed, yet one analyst on Wall Street sees a dramatically different story unfolding beneath the surface of the company's bruised financials.

117. ❖Aug 2, 1:14 PMnewsvia finnhub

     Abbott (ABT) Stock Looks Like A Bargain Below Fair Value

     Abbott Laboratories stock has fallen about 15% over the past year, yet a Discounted Cash Flow (DCF) intrinsic value estimate still points to meaningful upside compared with where the shares currently trade. At the same time, the broader valuation checks and market multiples suggest a picture that is closer to fair than clearly cheap. Over the past 12 months, Abbott Laboratories shares are down about 15%, which raises the question of whether recent weakness has already priced in key...

118. ❖Aug 2, 8:15 AMnewsvia finnhub

     Abbott Laboratories vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026?

     Abbott trades at half Lilly's valuation multiple, but Lilly's 45% revenue surge and 32% net margin raise the stakes for growth-focused investors.

119. ❖Jul 31, 3:49 PMnewsvia finnhub

     Abbott Laboratories vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

     Abbott trades at a cheaper valuation but carries higher litigation risk, while J&J boasts superior profitability despite a pending talc settlement.

120. ❖Jul 31, 10:42 AMnewsvia finnhub

     Guardant Health, Thursday's Stock Of The Day, Spikes After Hiking 2026 Outlook

     Guardant Health is Thursday's IBD Stock Of The Day in a thriving market for colon cancer screening tests. On Friday, Guardant Health stock surged after the company raised full-year outlook after a Q2 revenue beat late Thursday. Several analysts raised price targets on GH stock after the Q2 report, by as much as $50 a share, according to TheFly.com.

121. ❖Jul 31, 8:59 AMnewsvia finnhub

     AbbVie’s (NYSE:ABBV) Q2 CY2026: Beats On Revenue

     Pharmaceutical company AbbVie (NYSE:ABBV) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 10.2% year on year to $16.99 billion. Its non-GAAP profit of $3.65 per share was 1.2% above analysts’ consensus estimates.

122. ❖Jul 30, 1:38 PMnewsvia finnhub

     Guardant Health, Stock Of The Day, Offers Entry With Earnings Due

     Guardant Health is the IBD Stock Of The Day in a thriving market for colon cancer screening tests. Health and biotech stocks are acting well in the current market. Several biotech and health names can be found on the IBD 50 list of top growth stocks.

123. ❖Jul 30, 4:30 AMnewsvia finnhub

     Abbott Laboratories (NYSE:ABT): A Strong Candidate for Quality Investors

     Abbott Laboratories (ABT) meets quality investing criteria with strong 8.42% revenue growth, 19.34% ROIC, and near-perfect cash conversion, making it a compelling candidate for long-term investors.

124. ❖Jul 29, 3:40 PMnewsvia finnhub

     Best Dividend Aristocrats For August 2026

     NOBL beats SPY YTD in 2026; explore 25 undervalued Dividend Aristocrats with 10%+ projected returns and fresh dividend hikes—see the list now.

125. ❖Jul 29, 1:20 PMnewsvia finnhub

     3 Dividend Stocks to Buy for a Lifetime of Passive Income

     These companies' recent headwinds shouldn't lead to decreased payouts.

126. ❖Jul 29, 12:56 PMnewsvia finnhub

     AbbVie Has Raised Its Dividend for 53 Straight Years and Still Looks Attractively Valued. Is This Dividend King the Smartest Buy in Healthcare Right Now?

     AbbVie still looks like a compelling buy at its all-time high.

127. ❖Jul 29, 6:00 AMnewsvia finnhub

     Abbott starts TriClip study amid rising competition for heart valve repair

     Facing competition from Edwards, Abbott is studying TriClip’s real-world safety and performance in about 1,000 patients.

128. ❖Jul 28, 5:28 PMnewsvia finnhub

     These 3 Companies Reported Record Results and Raised Guidance

     Abbott Laboratories, Taiwan Semiconductor, and Johnson & Johnson have all delivered strong earnings releases in the Q2 cycle, with each breaking records while also lifting their outlooks.

129. ❖Jul 28, 1:30 PMnewsvia finnhub

     [Latest] Global Precision Diagnostics And Medicine Market Size/Share Worth USD 345.75 Billion by 2035 at a 8.91% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, SWOT Analysis)

     [220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Precision Diagnostics And Medicine Market size & share revenue was valued at approximately USD 147.23 Billion in 2025 and is expected to reach USD 159.66 Billion in 2026 and is expected to reach around USD 345.75 Billion by 2035, at a CAGR of 8.91% between 2026 and 2035. The key market players listed in the report with their sales, revenues and strategies are F. Hoff

130. ❖Jul 28, 12:04 PMnewsvia finnhub

     AllianceBernstein Q2 Earnings Call Highlights

     AllianceBernstein (NYSE:AB) reported record assets under management and its strongest quarterly sales in five years during the second quarter of 2026, as fixed-income demand, private-market deployments and insurance-related mandates helped the firm return to positive organic growth. Adjusted earnin

131. ❖Jul 28, 11:15 AMnewsvia finnhub

     UBS Maintains Buy on Abbott Laboratories, Lowers Price Target to $125

     UBS analyst Patrick Wood maintains Abbott Laboratories (NYSE:ABT) with a Buy and lowers the price target from $135 to $125.

132. ❖Jul 28, 9:29 AMnewsvia finnhub

     Abbott Rides Key Diabetes, Oncology and Heart Care Innovation Trends

     ABT is expanding across diabetes care, oncology diagnostics and heart devices, with new launches and acquisitions creating multiple growth paths to watch.

133. ▣Jul 26, 8:00 PMjournaltarget

     Agent 8 — Dip Buyer (Peer-Aware) closed long 12 @ $104.58 (+$202.31)

     Staged exit (1/2.0): close $104.58 ≥ target $103.84. Selling 12/25 sh, trailing remainder.

134. ✓Jul 17, 10:11 AMdecisionacted

     Agent 7 — Day Trader — decide: buy

     ABT is up 2.57% on what appears to be a strong Q2 2026 earnings beat — multiple headlines reference the earnings call highlights and 'strong growth in key segments,' and the pre-market headline 'Why Abbott Stock Jumped Today' confirms a fundamental catalyst. Earnings-driven gap-ups with clear fundamental justification tend to hold and grind higher into the close rather than fade, as institutional buyers layer in throughout the session. The macro backdrop is mixed: S&P 500 futures are dipping on tariff/energy worries and there is a broader tech sell-off, but ABT is a defensive healthcare/medtech name that is relatively insulated from tech-driven pressure and may even attract rotation flows. The low T10YIE print (2.22, 1.6σ below trend) is supportive of long-duration assets like dividend growth names, and ABT qualifies as a Dividend King per the headlines. With 335 minutes remaining there is ample time for continuation. No reversal pattern signals — the move appears to be holding rather than fading off highs. Overall, a solid fundamental catalyst plus defensive sector positioning plus supportive rates environment argues for continuation at a moderate-to-confident level.

135. ▢Jul 16, 8:00 PMjournal

     Agent 7 — Day Trader opened long 29 @ $101.37

136. ▣Jul 16, 8:00 PMjournalstop

     Agent 7 — Day Trader closed long 29 @ $99.78 (-$46.11)

     Long stop: close $99.78 ≤ stop $99.85

137. ?Jul 14, 9:42 AMdecisionconsidered

     Agent 7 — Day Trader — decide: skip

     ABT is down 3.20% intraday with no clear headline catalyst visible in recent news — the move likely reflects either sector rotation, earnings-adjacent flow, or broader healthcare pressure. The magnitude (~3.2%) is meaningful and suggests institutional selling with real conviction. The macro context (flat/slightly inverted curve, defensive sector sensitivity in a bear-flattening environment) is modestly negative for defensive healthcare names like ABT, as flattening can signal risk-off but also reduces appetite for defensive yield plays when rates remain uncertain. No reversal signal is evident — no news suggesting a catalyst that would snap back, no obvious morning-spike-and-fade pattern described. With 364 minutes remaining (essentially a full trading day still ahead), there is ample time for continuation. No strong reason to fade the move. Probability set at 0.54 — mild continuation bias given large move with sustained selling pressure, but tempered by absence of a clear fundamental catalyst and the defensive nature of the stock, which can see mean-reversion buying into the close.

138. ?Jul 13, 10:40 AMdecisionconsidered

     Agent 7 — Day Trader — decide: skip

     ABT is down 2.18% intraday with no clear headline catalyst driving the move — the only news is a bullish Baird initiation at Outperform, which if anything provides a modest headwind to further downside. The macro context (T10Y2Y at 2.1σ below trend) is modestly supportive of defensives like ABT, which could act as a stabilizer. However, the magnitude of the move (~2.18%) suggests real institutional selling flow, and with 305 minutes remaining (essentially a full trading day's worth of time left), there is ample runway for continuation if the selling pressure persists. The bullish initiation creates a natural support factor that could absorb further downside, and the macro backdrop leans defensive-supportive. Balancing the real momentum signal against the countervailing fundamental support (Baird Outperform) and macro tailwind for defensives, this is a borderline read. Assigning 0.50 — the move is real and time is ample, but counterforces are meaningful enough to prevent a higher conviction call.

139. ▣Jun 29, 8:00 PMjournalstop

     options_momentum closed long 100 @ $2.91 (-$83.69)

     Stop: premium $2.91 ≤ trailing floor $3.09 (peak $4.13 × 0.75)

140. ✓Jun 25, 1:35 PMdecisionacted

     options_momentum — decide: buy

     CALL on ABT — 5-day return 5.49% with close above 20-day MA ($89.13). IV 28.8%. Sized 1 contract(s) at $3.75 premium.

141. ✓Jun 25, 10:06 AMdecisionacted

     Agent 8 — Dip Buyer (Peer-Aware) — pyramid

     Pyramid add-on fired at +10.53% unrealized. Added 8 sh @ $93.80 ($750.40). Position now 25 sh @ weighted avg $87.72.

142. ▢Jun 24, 8:00 PMjournal

     options_momentum opened long 100 @ $3.75

143. ▣Jun 9, 8:00 PMjournalstop

     options_momentum closed long 200 @ $2.68 (-$160.47)

     Stop: premium $2.68 ≤ trailing floor $2.69 (peak $3.58 × 0.75)

144. ▢Jun 3, 8:00 PMjournal

     options_momentum opened long 200 @ $3.48

145. ▢Jun 1, 8:00 PMjournal

     Agent 7 — Day Trader opened long 17 @ $87.78

146. ▣Jun 1, 8:00 PMjournalstop

     Agent 7 — Day Trader closed long 17 @ $86.38 (-$23.80)

     Long stop: close $86.38 ≤ stop $86.46

147. ▣May 25, 8:00 PMjournalmanual

     options_momentum closed long 200 @ $2.32 (-$88.27)

     Stop: premium $1.99 ≤ trailing floor $2.08 (peak $2.77 × 0.75)

148. ▢May 19, 8:00 PMjournal

     options_momentum opened long 200 @ $2.76

149. ▢May 18, 8:00 PMjournal

     Agent 5 — Dip Buyer (Evolving) opened long 25 @ $84.86

150. ▣May 18, 8:00 PMjournalbank_funding

     Agent 5 — Dip Buyer (Evolving) closed long 25 @ $89.06 (+$105.00)

     Backfill 2026-05-19: closed at current mark to fund initial BANK sweep (highest unrealized P&L first; brings working equity to starting capital).

151. ▢May 18, 8:00 PMjournal

     Agent 8 — Dip Buyer (Peer-Aware) opened long 12 @ $87.72

152. ▢May 18, 8:00 PMjournal

     Agent 8 — Dip Buyer (Peer-Aware) opened long 13 @ $87.72